Mechanisms of Secondary Resistance to Idelalisib in Marginal Zone Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.128_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Development of Novel Preclinical Models of Secondary Resistance to the Pi3kδ Inhibitor Idelalisib in Splenic Marginal Zone Lymphoma (Smzl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Idelalisib and Rituximab in 17p Deletion–Positive Splenic Marginal Zone Lymphoma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2018English

Splenic Marginal Zone Lymphoma

2020English

Marginal Zone B-Cell Lymphoma

English

Changing Treatment Landscape of Marginal Zone Lymphoma

Integrative Clinical Medicine
2019English

A Case of Splenic Marginal Zone Lymphoma

Japanese Journal of Gastroenterological Surgery
SurgeryGastroenterology
2008English

Extranodal Marginal Zone Lymphoma of the Parotid Gland

Journal of Maxillofacial and Oral Surgery
OtorhinolaryngologyOral SurgerySurgery
2016English

Peripheral T-Cell Lymphoma Mimicking Marginal Zone B-Cell Lymphoma

Modern Pathology
Forensic MedicinePathology
2002English

Recurrent Autoimmune Hemolytic Anemia in Splenic Marginal Zone Lymphoma

Journal of Community Hospital Internal Medicine Perspectives
Internal Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy